P
Prestige BioPharma
Specializing in the discovery and development of innovative biologics and biosimilars
About Prestige BioPharma
Prestige BioPharma is a biopharmaceutical company focused on the discovery and development of innovative biologics and biosimilars. The company operates primarily in the APAC region but is rapidly expanding its footprint globally. Prestige BioPharma's core business involves the research and development of new antibody therapeutics and biosimilars, which are essentially generic versions of biologic drugs. These biosimilars are designed to be more affordable and accessible alternatives to existing biologic treatments, addressing unmet medical needs and providing cures for devastating diseases.
The company's flagship product, HD201 Trastuzumab, is currently in global Phase III clinical trials and is expected to launch in the market soon. Prestige BioPharma's business model revolves around leveraging its solid and innovative technology platform to develop a pipeline of biosimilar drugs that are in various stages of clinical and nonclinical development. By doing so, the company aims to become a leading player in the global biopharmaceutical market.
Revenue is generated through the commercialization of these biosimilars and new biologics, targeting healthcare providers, hospitals, and pharmaceutical companies that require cost-effective and high-quality therapeutic solutions.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Feb 2021 | $396M | $396M | Undisclosed | — |
| ACQUISITION✓Exit | Dec 2020 | $0 | — | Korea Securities Depository | — |
Growth signals
Latest recorded traffic for Prestige BioPharma is 3.8K monthly website visits, down 70.8% over the last three months. Prestige BioPharma's team grew 52.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Prestige BioPharma in the Singapore ecosystem
The Prestige BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors2 additional known investors
Korea Securities Depository
TS investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Prestige BioPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Prestige BioPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









